Aardvark Therapeutics, Inc. Common Stock (AARD)
$8.74 -$0.84 (-8.33%) 4:41 PM 05/14/25
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$284.41M -
Day's Range
$9.08 - $10.26 -
Volume
81,390 -
52 Week Low / High
$4.88 - $19.58 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
AARD's Dividend
Analyists Ranking
- 2
- Strong Buy
- 2
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong Sell
- -
- Target Price
Company News
-
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights — Mar 31st, 2025
Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome (PWS), with meaningful reductions in hyperphagia (up to a 16-point HQ-CT reduction, with an average reduction of approximately 8 points among subjects...
Similar Stocks
No similar stocks found.
|
Portfolio
$5,000/year
Goal: $10,000/year
Comprised of 1 portfolios
$